Loading
Drugs approved on early evidence come with follow-up obligations. One of them should be finding out how tumours escape the new drug.
Accelerated approvals already carry confirmatory trial requirements. Adding a resistance-characterisation commitment (a specified number of paired progression samples with mechanism reporting into a public database within a defined period) would ensure the field learns how each new agent fails while the drug is still early in its lifecycle, rather than a decade later.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Failures are hidden, Regulatory divergence between regions.
Shares Accelerated approval, Regulatory divergence between regions.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Accelerated approval, Regulatory divergence between regions.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.